Peptest has been described as a ‘cost‐effective, non-invasive measurement tool’ to assist office‐based diagnosis of laryngopharangeal reflux disease (LPR) in a new research paper.
The study, published in The Laryngoscope – the monthly peer-reviewed medical journal in the field of otolaryngology, delved into whether Peptest could lead to an improvement in the diagnosis of reflux.
Peptest detects the presence of pepsin – a proteolytic enzyme, activated by its precursor pepsinogen in the stomach, in saliva as well as secretion samples from the lung, sinus, middle ear, trachea, and exhaled breath condensate.
According to the ‘Pepsin and Oropharyngeal pH Monitoring to Diagnose Patients With Laryngopharyngeal Reflux’ study, its findings ‘underline the role of pepsin in the pathophysiology of laryngopharyngeal/extraoesophageal reflux symptoms’.
Notable observations from the study include:
- Patients showed the highest values of pepsin after lunch and dinner, which can be explained by the fact that heartburn likewise generally occurs one or two hours after a meal.
- Samples may have a more powerful ability to differentiate gastro-oesophageal reflux disease patients from non-GORD patients as well as patients with LPR from non-LPR.
- The results of this study show that salivary pepsin could be an alternative, cost-effective, non-invasive measurement tool to assist office-based diagnosis of LPR.
- Limitations of the study are cited as the lack of follow-up data to assess treatment outcomes after diagnostic decision based on salivary pepsin testing and that standardisation of meals was not included.
You can download the research paper here.